{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=36", "query": { "condition": "Malignant Melanoma, Metastatic", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 1026, "total_pages": 103, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Melanoma%2C+Metastatic&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:33:35.391Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02601378", "title": "A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "LXS196", "type": "DRUG" }, { "name": "LXS196 and HDM201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2016-02-01", "completion_date": "2022-01-07", "has_results": false, "last_update_posted_date": "2022-09-29", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601378" }, { "nct_id": "NCT06391099", "title": "Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dietary Intervention", "type": "OTHER" }, { "name": "Educational Activity", "type": "OTHER" }, { "name": "Glucose Measurement", "type": "OTHER" }, { "name": "Ketone Measurement", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-11-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06391099" }, { "nct_id": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SCLC", "Malignant Melanoma", "Sarcoma", "High Risk Neuroblastoma" ], "interventions": [ { "name": "GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 23, "start_date": "2022-11-17", "completion_date": "2026-03-11", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130255" }, { "nct_id": "NCT05572463", "title": "A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Cutaneous Melanoma", "Metastatic Cutaneous Melanoma" ], "interventions": [ { "name": "Sintilimab + IBI110", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-11-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2022-11-18", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 3, "location_summary": "San Francisco, California • Detroit, Michigan • Hackensack, New Jersey", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05572463" }, { "nct_id": "NCT05709821", "title": "IMM60 and Pembrolizumab in Melanoma and NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "IMM60", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iOx Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-11-15", "completion_date": "2024-04-22", "has_results": false, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05709821" }, { "nct_id": "NCT06246149", "title": "Adjuvant Tebentafusp in High Risk Ocular Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Tebentafusp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2024-11-11", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 1, "location_summary": "Lake Success, New York", "locations": [ { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06246149" }, { "nct_id": "NCT01551693", "title": "STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "STA-9090", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2011-09", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01551693" }, { "nct_id": "NCT06075524", "title": "Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Lung Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Metastatic Lung Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2015-06-15", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06075524" }, { "nct_id": "NCT02387125", "title": "Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Melanoma", "Non-small Cell Lung Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CMB305", "type": "BIOLOGICAL" }, { "name": "G100", "type": "BIOLOGICAL" }, { "name": "Metronomic CPA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 79, "start_date": "2015-02-28", "completion_date": "2019-03-29", "has_results": false, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 8, "location_summary": "Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387125" }, { "nct_id": "NCT06448364", "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Urothelial Cancer", "Melanoma" ], "interventions": [ { "name": "PF-07329640", "type": "BIOLOGICAL" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-05-09", "completion_date": "2024-08-15", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-10-15T17:33:35.391Z", "location_count": 4, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06448364" } ] }